<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04038125</url>
  </required_header>
  <id_info>
    <org_study_id>LCH-0-012-019</org_study_id>
    <nct_id>NCT04038125</nct_id>
  </id_info>
  <brief_title>Increase in Capillary Plexus Density Level Following the Use of Ozurdex for the Treatment of DME</brief_title>
  <acronym>ICOD</acronym>
  <official_title>Increase in Capillary Plexus Density Level Following the Use of Ozurdex for the Treatment of DME (RMSM ICOD STUDY)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Retina Macula Specialists of Miami, LLC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Retina Macula Specialists of Miami, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to test the hypothesis that following the use of intravitreal
      dexamethasone implant for the treatment of DME, there will be an observable increase in the
      capillary density plexus as denoted by the quantitative assessment of the superficial
      capillary plexus on OCTA, as well as a decrease in size of the foveal avascular zone (FAZ).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 22, 2019</start_date>
  <completion_date type="Anticipated">August 2021</completion_date>
  <primary_completion_date type="Anticipated">August 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate re perfusion following Ozurdex use.</measure>
    <time_frame>6 Months</time_frame>
    <description>Determined by OCT-A</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Diabetic Macular Edema</condition>
  <condition>Diabetic Retinopathy</condition>
  <condition>Retinal Ischemia</condition>
  <arm_group>
    <arm_group_label>Ozurdex Implant</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Intravitreal injection of Ozurdex implant</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ozurdex Drug Implant Product</intervention_name>
    <description>Intravitreal Ozurdex injection</description>
    <arm_group_label>Ozurdex Implant</arm_group_label>
    <other_name>Dexamethasone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age ≥ 18 years and Older.

          2. Diagnosis of diabetes mellitus (type 1 or type 2).

          3. At least one eye meets the study eye criteria listed.

          4. Visual Acuity 20/30 - 20/200 Snellen equivalent

          5. Have received no previous treatment for diabetic macular edema,(treatment naïve)

          6. Mild to Severe Non-proliferative Diabetic Retinopathy

          7. Diabetic macular edema present on optical coherence tomography (OCT) central subfield:
             ≥ 300µm.

          8. Able and willing to provide informed consent.

        Exclusion Criteria:

          1. Have had any prior ocular treatment.

          2. Have had prior retinal surgical ( i.e. Pars plana vitrectomy). 3 .Have any clinical
             evidence of proliferative diabetic retinopathy.

        4. Have a HBA1c of greater of 10%. 5. Evidence of Glaucoma or who are labeled glaucoma
        suspect at screening (defined as C/D &gt;/= 0.5 with correlated NFLA thinning or IOP&gt;25mmHg).
        6. Have a contraindication to Ozurdex.
      </textblock>
    </criteria>
    <gender>All</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Diana Shechtman, OD FAAO</last_name>
    <role>Principal Investigator</role>
    <affiliation>Retina Macula Specialists of Miami, LLC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Diana Shechtman, OD FAAO</last_name>
    <phone>954-816-1038</phone>
    <email>dshehctman@retinamiami.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Pamela Garcia, CCRC</last_name>
    <phone>305-643-8871</phone>
    <email>pjimenez@retinamiami.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Retina Macula Specialists of Miami, LLC</name>
      <address>
        <city>North Miami Beach</city>
        <state>Florida</state>
        <zip>33162</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joyce Gonzalez</last_name>
      <phone>305-655-0411</phone>
      <email>jgonzalez@retinamiami.com</email>
    </contact>
    <contact_backup>
      <last_name>Pamela Garcia</last_name>
      <phone>306-643-8871</phone>
      <email>pjimenez@retinamiami.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Retina Macula Specialists of Miami, LLC</name>
      <address>
        <city>South Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joyce Gonzalez</last_name>
      <phone>305-666-8850</phone>
      <email>jgonzalez@retinamiami.com</email>
    </contact>
    <contact_backup>
      <last_name>Pamela Garcia</last_name>
      <phone>305-643-8871</phone>
      <email>Pjimenez@retinamiami.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>July 26, 2019</study_first_submitted>
  <study_first_submitted_qc>July 29, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 30, 2019</study_first_posted>
  <last_update_submitted>March 16, 2020</last_update_submitted>
  <last_update_submitted_qc>March 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Retina Macula Specialists of Miami, LLC</investigator_affiliation>
    <investigator_full_name>Diana Shechtman, OD FAAO</investigator_full_name>
    <investigator_title>Principal Investigator - OD, FAAO</investigator_title>
  </responsible_party>
  <keyword>Diabetic Macula Edema</keyword>
  <keyword>Diabetic Retinopathy</keyword>
  <keyword>Retina Ischemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Edema</mesh_term>
    <mesh_term>Retinal Diseases</mesh_term>
    <mesh_term>Diabetic Retinopathy</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

